All In Biotech

Drug Trial Radar · NCT06148792

A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria

A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria - TAfenoquine DOsing REvised

Last checked: Nov 19, 2026Latest source record: Jul 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,090 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,090

Planned (sponsor's estimate)

Start

May 10, 2024

Primary completion

Mar 1, 2027

Study completion Mar 1, 2027

Sponsor

Lead sponsor
Menzies School of Health ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Melbourne; Fundação de Medicina Tropical Dr. Heitor Vieira Dourado; Arba Minch University; Addis Ababa University; Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Indonesia; Curtin University; Papua New Guinea Institute of Medical Research
First posted
Nov 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the efficacy and safety or a revised weight band tafenoquine dose in vivax malaria patients. The main question\[s\] it aims to answer are: * is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg/kg) non-inferior to high dose primaquine (7mg/kg over 7 days) * is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg/kg) superior to fixed dose tafenoquine (300mg) * is the tolerability and safety of TQRevised acceptable * is TQRevised acceptable and feasible Participants will receive a tafenoquine target dose 7.5mg/kg in weight bands. Researchers will compare this to patients receiving a fixed dose tafenoquine and high dose primaquine to see if safe and effective.

Conditions

  • Vivax Malaria

Interventions

  • TafenoquineDrug

    oral treatment

  • PrimaquineDrug

    oral treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence risk of vivax parasitaemiaTime frame: 4 months

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Dr Marcus Lacerda

    Manaus, Brazil · Recruiting

  • Arba Minch General Hospital

    Arba Minch, Ethiopia · Recruiting

  • Puskesmas Hanura

    Hanura, Indonesia · Not yet recruiting

  • Dr Moses Laman and Dr Brioni Moore

    Alexishafen, Papua New Guinea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.